Astria Therapeutics Inc (ATXS)

Currency in USD
6.280
-0.390(-5.85%)
Closed·
After Hours
6.2800.000(0.00%)
·
ATXS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ATXS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.2006.670
52 wk Range
3.55512.920
Key Statistics
Prev. Close
6.67
Open
6.67
Day's Range
6.2-6.67
52 wk Range
3.555-12.92
Volume
177.44K
Average Volume (3m)
387.62K
1-Year Change
-36.88%
Book Value / Share
3.44
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATXS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
28.889
Upside
+360.01%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Astria Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Astria Therapeutics Inc Company Profile

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Compare ATXS to Peers and Sector

Metrics to compare
ATXS
Peers
Sector
Relationship
P/E Ratio
−3.3x−3.1x−0.5x
PEG Ratio
−0.19−0.010.00
Price/Book
1.8x2.2x2.6x
Price / LTM Sales
-9.5x3.3x
Upside (Analyst Target)
350.9%196.4%43.5%
Fair Value Upside
Unlock6.5%6.8%Unlock

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 28.889
(+360.01% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.58 / -0.45
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ATXS Income Statement

People Also Watch

50.46
AKRO
+0.02%
62.000
CDTX
+0.44%
11.16
DYN
-0.27%
3.45
ALT
-1.99%
109.55
INSM
+0.23%

FAQ

What Stock Exchange Does Astria Therapeutics Trade On?

Astria Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Astria Therapeutics?

The stock symbol for Astria Therapeutics is "ATXS."

What Is the Astria Therapeutics Market Cap?

As of today, Astria Therapeutics market cap is 354.41M.

What Is Astria Therapeutics's Earnings Per Share (TTM)?

The Astria Therapeutics EPS (TTM) is -1.88.

When Is the Next Astria Therapeutics Earnings Date?

Astria Therapeutics will release its next earnings report on 10 Aug 2025.

From a Technical Analysis Perspective, Is ATXS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Astria Therapeutics Stock Split?

Astria Therapeutics has split 3 times.

How Many Employees Does Astria Therapeutics Have?

Astria Therapeutics has 78 employees.

What is the current trading status of Astria Therapeutics (ATXS)?

As of 09 Aug 2025, Astria Therapeutics (ATXS) is trading at a price of 6.28, with a previous close of 6.67. The stock has fluctuated within a day range of 6.20 to 6.67, while its 52-week range spans from 3.56 to 12.92.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.